Evidence map›Paper›PMID 38886817›Full record

ArticleStem cell research & therapy2024

Combination of induced pluripotent stem cell-derived motor neuron progenitor cells with irradiated brain-derived neurotrophic factor over-expressing engineered mesenchymal stem cells enhanced restoration of axonal regeneration in a chronic spinal cord injury rat model.

Jang-Woon Kim, Juryun Kim, Soon Min Lee, Yeri Alice Rim, Young Chul Sung, Yoojun Nam, Hyo-Jin Kim, Hyewon Kim, Se In Jung, Jooyoung Lim and 1 more

Abstract read
In one paragraph

Article in Stem cell research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jang-Woon KimCiSTEM laboratory, Catholic iPSC Research Center (CiRC), College of Medicine, The Catholic University of Korea, Seoul, 137-701, Republic of Korea.
Juryun KimYiPSCELL, Inc., Seoul, Republic of Korea.
Soon Min LeeSL BiGen, Inc., Incheon, Republic of Korea.
Yeri Alice RimCiSTEM laboratory, Catholic iPSC Research Center (CiRC), College of Medicine, The Catholic University of Korea, Seoul, 137-701, Republic of Korea.
Young Chul SungSL BiGen, Inc., Incheon, Republic of Korea.
Yoojun NamYiPSCELL, Inc., Seoul, Republic of Korea.
Hyo-Jin KimSL BiGen, Inc., Incheon, Republic of Korea.
Hyewon KimYiPSCELL, Inc., Seoul, Republic of Korea.
Se In JungCiSTEM laboratory, Catholic iPSC Research Center (CiRC), College of Medicine, The Catholic University of Korea, Seoul, 137-701, Republic of Korea.
Jooyoung LimCiSTEM laboratory, Catholic iPSC Research Center (CiRC), College of Medicine, The Catholic University of Korea, Seoul, 137-701, Republic of Korea.
Ji Hyeon JuCiSTEM laboratory, Catholic iPSC Research Center (CiRC), College of Medicine, The Catholic University of Korea, Seoul, 137-701, Republic of Korea. juji@catholic.ac.kr.ORCID 0009-0001-7649-5076

Funding

Catholic Institute of Cell Therapy CRC in 2024College of Medicine, Catholic University of Korea College of Medicine, Catholic University of KoreaMinistry of Science, ICT and Future Planning NRF-2019R1A5A2027588Ministry of Science, ICT and Future Planning NRF-2021R1C1C2004688
6 · The paper itself

Abstract

backgroundSpinal cord injury (SCI) is a disease that causes permanent impairment of motor, sensory, and autonomic nervous system functions. Stem cell transplantation for neuron regeneration is a promising strategic treatment for SCI. However, selecting stem cell sources and cell transplantation based on experimental evidence is required. Therefore, this study aimed to investigate the efficacy of combination cell transplantation using the brain-derived neurotrophic factor (BDNF) over-expressing engineered mesenchymal stem cell (BDNF-eMSC) and induced pluripotent stem cell-derived motor neuron progenitor cell (iMNP) in a chronic SCI rat model.

methodA contusive chronic SCI was induced in Sprague-Dawley rats. At 6 weeks post-injury, BDNF-eMSC and iMNP were transplanted into the lesion site via the intralesional route. At 12 weeks post-injury, differentiation and growth factors were evaluated through immunofluorescence staining and western blot analysis. Motor neuron differentiation and neurite outgrowth were evaluated by co-culturing BDNF-eMSC and iMNP in vitro in 2-dimensional and 3-dimensional.

resultsCombination cell transplantation in the chronic SCI model improved behavioral recovery more than single-cell transplantation. Additionally, combination cell transplantation enhanced mature motor neuron differentiation and axonal regeneration at the injured spinal cord. Both BDNF-eMSC and iMNP played a critical role in neurite outgrowth and motor neuron maturation via BDNF expression.

conclusionsOur results suggest that the combined transplantation of BDNF- eMSC and iMNP in chronic SCI results in a significant clinical recovery. The transplanted iMNP cells predominantly differentiated into mature motor neurons. Additionally, BDNF-eMSC exerts a paracrine effect on neuron regeneration through BDNF expression in the injured spinal cord.

Indexed as

Brain-Derived Neurotrophic FactorDisease Models, AnimalInduced Pluripotent Stem CellsMesenchymal Stem CellsMesenchymal Stem Cell TransplantationMotor NeuronsNerve RegenerationRats, Sprague-DawleySpinal Cord InjuriesAnimalsAxonsCell DifferentiationNeural Stem CellsRatsBrain-Derived Neurotrophic FactorBDNF over-expressing engineered mesenchymal stem cellChronic spinal cord injuryCombination cell transplantationInduced pluripotent stem cell-derived motor neuron progenitor cell

Identifiers

PMID38886817
PMCPMC11184802

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.